dA(Bz)-CPG co-polymer coated

Technical Description

What is dA(Bz)?

dA(Bz) is a protected deoxyadenosine monomer used in DNA oligonucleotide synthesis.
Its specific chemical designation is N⁶-benzoyl (Benzoyl, Bz)–protected deoxyadenosine.

Bz is a base-protecting group introduced at the N⁶ position of adenine, and its core functions include:

• Improvement of coupling efficiency:
  enhancing the chemical reactivity during each synthesis cycle.
• Prevention of side reactions:
  protecting the adenine base from undesired acylation or depurination reactions during synthesis.

About DMT-dA(Bz)-CPG (Co-polymer)

DMT-dA(Bz)-CPG is a standard solid-phase support for automated DNA synthesis.

• With a DMT group:
  used for standard chain elongation.
• Without a DMT group:
  mainly applied in customized synthesis routes or for special 5′-end modifications.

Why is the dA base commonly used at the starting position (3′ end) of oligonucleotides?

In the design of biological sequences such as PCR primers, probes, sgRNA, and ASOs,
the 3′ terminus is often designed to start with an adenine base, primarily based on the following considerations:

• Structural optimization:
  incorporation of a dA base at the 3′ position is less prone to forming strong secondary structures,
  thereby reducing steric hindrance at the initiation site.
• Chemical stability:
  CPG solid supports linked with dA(Bz) exhibit the most stable chemical structure,
  which is most favorable for synthesis.
• Advantages in long-chain synthesis (≥100 nt):
  in long-chain applications (e.g., CRISPR gRNA),
  using an A base at the 3′ end effectively reduces coupling issues caused by excessive GC content,
  significantly improving the yield of full-length products (FLP).

Core Advantages of Poresyn Solutions’ Novel Co-polymer Coated CPG (with dA(Bz))

The use of our novel CPG architecture enables breakthrough improvements for large-scale industrial production:

• Ultra-high loading capacity:
  the loading is 3–6 times higher than that of conventional modified CPG.
  This directly addresses the bottleneck of kilogram-scale oligonucleotide drug manufacturing
  and makes it an ideal choice for GMP-grade industrial production.
• Exceptional crude purity:
  crude product purity can be increased to above 80%,
  significantly reducing the burden of downstream purification
  and lowering the overall cost of goods (COG).
• Physically stable architecture:
  due to the unique physical interaction between the polymer resin and the glass particle surface,
  this support exhibits superior resistance to both acidic and basic conditions.
• No swelling and no backpressure risk:
  the physical structure remains highly stable during synthesis without swelling,
  preventing synthesis failures caused by increased backpressure
  and ensuring safe and controllable industrial operation.
• Enhanced linkage stability:
  when linking bases such as dA(Bz),
  this architecture provides higher linkage stability
  and superior synthesis performance compared with conventional CPG.